Mizuho Securities USA LLC Purchases 16,838 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mizuho Securities USA LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 43.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,900 shares of the medical research company's stock after acquiring an additional 16,838 shares during the period. Mizuho Securities USA LLC's holdings in Edwards Lifesciences were worth $4,138,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in EW. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $29,000. FSA Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $30,000. Avior Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after purchasing an additional 308 shares during the period. Finally, Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $46,000. Institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on EW shares. Royal Bank of Canada restated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Piper Sandler increased their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Citigroup raised their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Finally, Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and upped their price target for the company from $82.00 to $90.00 in a research report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $79.95.

Remove Ads

Edwards Lifesciences Price Performance

Shares of EW stock traded up $0.08 during trading on Thursday, hitting $71.17. The company had a trading volume of 3,079,151 shares, compared to its average volume of 4,619,138. The stock's 50-day moving average is $71.45 and its two-hundred day moving average is $70.45. The stock has a market capitalization of $41.84 billion, a price-to-earnings ratio of 10.21, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Bernard J. Zovighian sold 6,164 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. The trade was a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the company's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company's stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,553 shares of company stock valued at $4,513,064 over the last 90 days. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.